Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BNTX

BioNTech SE

Tremor tracks 23 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • BNTXBioNTech SE
    0Calm

    Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

    Running, no new patientsPhase 2110 patientsMain results: Jun 2027
  • BNTXBioNTech SE
    0Calm

    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

    Signing up patientsPhase 2/31,580 patientsMain results: Jan 2029
  • BNTXBioNTech SE
    0Calm

    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    Signing up patientsPhase 3558 patientsMain results: Dec 2029
  • BNTXBioNTech SE
    0Calm

    A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

    Signing up patientsPhase 275 patientsMain results: Jan 2028
  • BNTXBioNTech SE
    0Calm

    A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

    Running, no new patientsPhase 2/3358 patientsMain results: Apr 2029
  • BNTXBioNTech SE
    0Calm

    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    Signing up patientsPhase 1/2880 patientsMain results: Nov 2028
  • BNTXBioNTech SE
    0Calm

    A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn

    Not started yetPhase 1/2173 patientsMain results: Oct 2029
  • BNTXBioNTech SE
    0Calm

    A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

    Signing up patientsPhase 3480 patientsMain results: Mar 2028
  • BNTXBioNTech SE
    0Calm

    A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    Signing up patientsPhase 3736 patientsMain results: Feb 2031
  • BNTXBioNTech SE
    0Calm

    A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    Signing up patientsPhase 1/2380 patientsMain results: Aug 2029
  • BNTXBioNTech SE
    0Calm

    A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

    Signing up patientsPhase 1/2245 patientsMain results: May 2030
  • BNTXBioNTech SE
    0Calm

    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

    Signing up patientsPhase 3621 patientsMain results: Apr 2029
  • BNTXBioNTech SE
    0Calm

    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    Signing up patientsPhase 1/21,438 patientsMain results: Mar 2028
  • BNTXBioNTech SE
    0Calm

    A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

    Running, no new patientsPhase 2327 patientsMain results: Nov 2026
  • BNTXBioNTech SE
    0Calm

    Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

    Signing up patientsPhase 1/2248 patientsMain results: Apr 2031
  • BNTXBioNTech SE
    0Calm

    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

    Signing up patientsPhase 1/2594 patientsMain results: Sep 2028
  • BNTXBioNTech SE
    0Calm

    Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

    Signing up patientsPhase 1/2533 patientsMain results: Oct 2030
  • BNTXBioNTech SE
    0Calm

    A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

    Signing up patientsPhase 2105 patientsMain results: Dec 2027
  • BNTXBioNTech SE
    0Calm

    A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

    Signing up patientsPhase 1/2482 patientsMain results: Dec 2030
  • BNTXBioNTech SE
    0Calm

    Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

    Running, no new patientsPhase 283 patientsMain results: Aug 2028
  • BNTXBioNTech SE
    0Calm

    A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

    Signing up patientsPhase 1/2375 patientsMain results: Nov 2027
  • BNTXBioNTech SE
    0Calm

    Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

    Signing up patientsPhase 260 patientsMain results: Oct 2028
  • BNTXBioNTech SE
    0Calm

    A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

    FinishedPhase 2184 patientsMain results: Jan 25, 2024

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

26 sales (0 not pre-planned) · 0 purchases

  • Sahin UgurChief Executive Officer · Oct 9, 2026Sold 36,209 sharesabout $3.5 million · pre-planned
  • Sahin UgurChief Executive Officer · Oct 8, 2026Sold 27,000 sharesabout $2.5 million · pre-planned
  • Sahin UgurChief Executive Officer · Oct 7, 2026Sold 24,000 sharesabout $2.3 million · pre-planned
  • Sahin UgurChief Executive Officer · Oct 6, 2026Sold 21,000 sharesabout $2.0 million · pre-planned
  • Sahin UgurChief Executive Officer · Oct 5, 2026Sold 72,000 sharesabout $7.0 million · pre-planned
  • Sahin UgurChief Executive Officer · Oct 2, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • None in the last 12 months.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.
Sold 17,000 sharesabout $1.6 million · pre-planned
  • Sahin UgurChief Executive Officer · Oct 1, 2026Sold 17,000 sharesabout $1.7 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 30, 2026Sold 32,000 sharesabout $3.1 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 29, 2026Sold 34,000 sharesabout $3.3 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 28, 2026Sold 34,000 sharesabout $3.3 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 25, 2026Sold 27,000 sharesabout $2.7 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 24, 2026Sold 39,000 sharesabout $3.9 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 23, 2026Sold 30,000 sharesabout $3.0 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 22, 2026Sold 46,000 sharesabout $4.6 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 21, 2026Sold 33,000 sharesabout $3.2 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 18, 2026Sold 30,000 sharesabout $2.9 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 17, 2026Sold 34,000 sharesabout $3.4 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 16, 2026Sold 15,000 sharesabout $1.4 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 15, 2026Sold 34,000 sharesabout $3.3 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 14, 2026Sold 41,000 sharesabout $4.1 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 11, 2026Sold 45,000 sharesabout $4.4 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 10, 2026Sold 20,500 sharesabout $2.0 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 9, 2026Sold 36,000 sharesabout $3.5 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 8, 2026Sold 37,000 sharesabout $3.7 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 4, 2026Sold 31,500 sharesabout $3.3 million · pre-planned
  • Sahin UgurChief Executive Officer · Sep 3, 2026Sold 45,000 sharesabout $4.6 million · pre-planned